Precision Medicine of Diabetes Program in China
- Disease/Condition
- Diabetes
- Drug/Device/Intervention
- no intervention
- Study type
- Observational
- Intervention type
- other
- Primary sponsor
- Second Xiangya Hospital of Central South University
- Location
- Changsha, China
- Phase
- N/A
- Start date
- Jul 01, 2023
- End date
- Dec 01, 2028
- Enrollment
- 120000 participants
The currency analysis of diabetes classification
The prevalence of diabetes has been increasing year by year. According to the International
 Diabetes Federation (IDF) statistics in 2021, the global number of people with diabetes has
 reached 537 million. The patient population is large and heterogeneous, and precise diagnosis
 and treatment of diabetes patients have been a focus of attention. The objective of this
 study is to clarify the current status of precision classification and diagnosis of diabetes
 patients through retrospective and prospective cohort studies, and to establish a model for
 precision classification and diagnosis of diabetes, improving the accuracy of diabetes
 classification and diagnosis; based on big data of precision medicine for diabetes patients
 and follow-up cohorts, to establish precise diagnostic, therapeutic, and predictive methods
 for diabetes; and through multi-omics data analysis, to explore the potential pathogenesis of
 diabetes, explaining the heterogeneity of patients, and guiding individualized treatment for
 patients.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06320600
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06320600 through Pure Global AI's free database. This phase not specified trial is sponsored by Second Xiangya Hospital of Central South University and is currently Recruiting. The study focuses on Diabetes. Target enrollment is 120000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.